Polo-like Kinase 1 as a Target for Anti-tumor Therapy


Klin Onkol 2015; 28(Suppl 2): 32-39. DOI: 10.14735/amko20152S32.

Summary Individual proteins from polo-like kinase (Plk) family fulfil different but critical functions in regulating cell cycle and coordinate cell response to DNA- damage. The most studied one from this five- member family is Plk1. It is a serine/ threonine kinase that plays a pivotal role in many aspects of mitosis and its deregulation is common in various tumor types where the elevated level is mostly associated with worse prognosis. From the therapeutical point of view, intertwin ed relationship between Plk1 and p53 protein is very interesting and will be discussed. Not only for these reasons, Plk1 has become an attractive target for anti-tumor drug development. The most promising seems to be ATP-binding site inhibitor Volasertib (BI 6727) which provided a survival benefit for patients with acute myeloid leukemia and is now tested in phase III clinical trial. A new generation of Plk1 inhibitors that target the second druggable domain of Plk1, the polo-box domain, is currently being tested preclinically and are believed to improve Plk1 specificity.


Full text in PDF